Orexo AB ORX

STO: ORX | ISIN: SE0000736415   27/06/2025
19,24 SEK (-1,54%)
(-1,54%)   27/06/2025

10 april 2025 · Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology · Persbericht

3 september 2024 · Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 · Persbericht

17 juli 2024 · Orexo Q2 2024 Interim Report · Persbericht

16 juli 2024 · Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose · Persbericht

10 juli 2024 · Orexo AB´s sustainability work ranked among top 5% by EcoVadis · Persbericht

8 juli 2024 · Orexo: invitation to presentation of the Q2 2024 Interim Report · Persbericht

10 mei 2024 · Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm · Persbericht

8 mei 2024 · Orexo Q1 2024 Interim Report · Persbericht

26 april 2024 · Report from Orexo AB's annual general meeting, 26 April 2024 · Persbericht

17 april 2024 · Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US · Persbericht

2 april 2024 · Orexo announces that the condition for early redemption of its existing bonds has been fulfilled · Persbericht

28 maart 2024 · Orexo publishes the Annual and Sustainability Report for 2023 · Persbericht

22 maart 2024 · Correction: Notice of Annual General Meeting of Orexo · Persbericht

15 maart 2024 · Notice of Annual General Meeting of Orexo · Persbericht

13 maart 2024 · Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds · Persbericht

8 maart 2024 · Orexo strengthens its sustainability work by establishing a social financing framework · Persbericht

8 maart 2024 · Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds · Persbericht

12 februari 2024 · Orexo and Sobi agree to advance feasibility study with AmorphOX · Persbericht

8 februari 2024 · Orexo Interim Report Q4 2023, incl. Full Year Report · Persbericht

6 februari 2024 · Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC · Persbericht

Mijn selecties